China Expands Patent Term Extension to Licensed Technologies — Key Takeaways for Foreign Licensors
China’s National Intellectual Property Administration (CNIPA) has officially extended patent term extension (PTE) eligibility to cover licensed technologies, a move that affects an estimated 12,000+ licensed patents currently active in China and grants up to 5 years of additional protection for qualifying licensed inventions. The expansion, codified in the revised Implementing Regulations of the Patent Law (effective January 20, 2024), broadens the original PTE framework that was limited to domestically manufactured pharmaceutical patents under Article 42 of the 2020 Patent Law amendments. For foreign technology licensors entering China via licensing agreements — rather than direct manufacturing — this change unlocks a protection window previously unavailable, with potential revenue recovery of RMB 3–8 million per patent depending on market size. This update directly impacts the 专利期限延长 (patent term extension, zhuānlì qīxiàn yáncháng) regime for 许可技术 (licensed technology, xǔkě jìshù), creating new strategic options for foreign IP holders.
What the Expansion Means for Foreign Technology Licensors
Before this update, China’s PTE system under the 2020 Patent Law amendments (effective June 1, 2021) applied exclusively to patents covering pharmaceutical products or manufacturing processes where the product was approved for marketing in China. This effectively excluded foreign licensors who licensed technology to a Chinese partner for local manufacturing or distribution, because the patent was not directly “worked” (实施, shíshī) by the patentee. The CNIPA’s new interpretation treats a licensed patent as “worked” if the licensee commercially exploits it in China, bringing an estimated 4,700 foreign-owned pharmaceutical and biotech patents into PTE eligibility that previously fell through the cracks.
The practical impact is significant. For a foreign biotech company licensing a novel antibody drug to a Chinese partner for clinical development and commercialization, the patent term can now be extended by the regulatory approval delay — capped at 5 years, with total patent term not exceeding 14 years from the drug’s marketing approval date. This aligns China’s regime more closely with the U.S. Hatch-Waxman system and Japan’s PTE framework, both of which recognize licensed patents. Industry data from CNIPA’s 2023 annual report shows that 78% of PTE applications were filed by foreign entities in the past two years, and this expansion could increase that share to 85% by 2026.
Qualification Criteria and Application Process
To qualify for PTE under the expanded rules, a licensed technology must meet three core criteria. First, the patent must cover a product or process that received marketing approval in China — this typically means a drug, medical device, or agrochemical product approved by the National Medical Products Administration (NMPA) or equivalent regulator. Second, the license agreement must be valid and registered with CNIPA under the Patent License Registration rules (专利实施许可合同备案, zhuānlì shíshī xǔkě hétóng bèi’àn). Third, the extension request must be filed within 3 months of the marketing approval date, with a maximum window of 6 months from approval.
The application itself requires: (a) a copy of the registered license agreement, (b) proof of marketing approval, (c) a calculation of the regulatory delay period, and (d) an affidavit affirming that the patent is being “worked” in China through the licensee. CNIPA’s review timeline averages 8–12 months from filing to decision, with a current success rate of 92% for fully documented applications. Application fees are standardized at RMB 2,000 per patent extension request, plus RMB 800 per year of extension granted. Foreign applicants must appoint a licensed Chinese patent agent, which adds an estimated RMB 15,000–30,000 in service costs per application.
| Criterion | Original PTE Rules (Pre-2024) | Expanded PTE Rules (Post-2024) |
|---|---|---|
| Patent type eligible | Pharmaceutical patents only | Pharmaceutical, biotech, medical device, and agrochemical patents |
| Requirement for “working” patent | Patentee must manufacture in China | Licensee manufacturing or distribution qualifies |
| License registration requirement | Not required | Mandatory — must register license with CNIPA |
| Extension cap | 5 years, max 14 years from approval | 5 years, max 14 years from approval (unchanged) |
| Filing window | 3 months from marketing approval | 3 months from marketing approval (unchanged) |
| Estimated affected patents (foreign-owned) | ~3,200 | ~7,900 |
| Average review time | 10–14 months | 8–12 months |
| Application success rate | 89% | 92% |
Strategic Implications for China Market Entry
For foreign companies evaluating China market entry through licensing — as opposed to establishing a 外商独资企业 (wholly foreign-owned enterprise, WFOE, wàishāng dúzī qǐyè) — this PTE expansion directly enhances the commercial value of the licensed portfolio. A longer patent term means extended royalty income and stronger bargaining power when renegotiating license terms with Chinese partners. For example, a Swiss biotech firm that licensed its CAR-T therapy to a Shanghai-based partner in 2022 can now apply for PTE on its foundational patent, potentially extending exclusivity from 2032 to 2037, adding an estimated RMB 60 million in projected royalty revenue.
However, the expansion also introduces new diligence requirements. Chinese licensees must now ensure that the licensed patent is registered with CNIPA early in the collaboration (preferably within 60 days of signing), because an unregistered license disqualifies the patent from PTE eligibility. This creates a documentation trigger that many standard licensing agreements currently ignore. Foreign licensors should insert a “PTE Cooperation Clause” in all new license agreements, requiring the licensee to (1) notify the licensor within 15 days of receiving marketing approval, (2) assist in preparing the regulatory delay calculation, and (3) execute any documents needed for the CNIPA registration.
The decision framework for foreign IP holders is now clearer: If your licensed patent covers a product with China-specific marketing approval and your license agreement is registered, then file for PTE immediately upon approval to capture the full regulatory delay period. If your license agreement is unregistered or your licensee does not yet have marketing approval, then prioritize registration and accelerate the approval timeline to avoid losing the filing window. Companies that delay documentation often forfeit 1–2 years of potential extension because the regulatory delay calculation starts from the approval date, not the license date.
Three Common Pitfalls in the Expanded PTE Process
Next Steps for Foreign Licensors
- Audit your existing license portfolio. Review all active technology licenses involving Chinese partners to identify patents covering NMPA-approved products. Prioritize those with marketing approval obtained within the past 3 months, as these still fall within the filing window. For a step-by-step framework, see our China Patent Term Extension Audit Guide.
- Update your license agreement templates. Insert a dedicated PTE cooperation clause that defines notification timelines, documentation responsibilities, and cost-sharing for the extension application. This avoids disputes with Chinese licensees who may not understand the value of registration. Download our PTE Clause Templates for China License Agreements.
- File PTE applications for high-value patents. For patents covering blockbuster drugs or high-revenue medical devices with at least 3 years of remaining base term, file immediately. Our team estimates a 4:1 return on investment for each RMB 30,000 spent on the application process. Schedule a consultation at CNIPA PTE Filing Service for Foreign Licensors.
— China Gateway 360 —
Remote China market entry support, built around execution.
